Emplicure AB has received a grant of 50 000 EUR from EIT Health, a Knowledge and Innovation Community (KIC) established by the European Institute for Innovation & Technology (EIT) to promote innovation and entrepreneurship across Europe. The grant will be used to accelerate the development of an abuse deterrent transdermal patch for the treatment of pain. The patch is based on controlled release of the active substance from a ceramic material making the treatment safer for the patients, their families and lower the risk to public health as the formulation has barriers against misuse and abuse e.g. via smoking and oral ingestion. The project is performed in collaboration with Uppsala university, Department of Engineering Sciences, Applied Materials Science, Professor Håkan Engqvist.
Emplicure AB has developed the formulation of Empli03 to be used for GMP manufacturing for the first clinical study. Agreement has been signed with Quotient Sciences, UK, who will be responsible for the manufacturing and will also perform the first pharmacokinetic study.
Emplicure AB announces today that the Nomination Committee for the annual general shareholders meeting (AGM) in April 2022 is formed. The Nomination Committee consists of representatives nominated by the three largest shareholders per the last bank-day in the third quarter, as well as the Chairman of the Board. Emplicure's three largest shareholders, also the founders, have agreed to vote as one, in order to to give preference for more shareholders.
Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic pain, and Amp01, our oral tobacco-free nicotine product in the form of dry, white pouches as a consumer product. Both projects are developed on our own bioceramic and patented technologies and platforms.
Anna-Lena Nicolson, CFO och medlem i ledningsgruppen i Emplicure AB (publ), har idag beslutat att lämna sitt uppdrag. Anna-Lena kommer att kvarstå som CFO till och med den 31 december 2021. Processen med att rekrytera hennes ersättare har inletts.